

News Release

No.23025  
December 15, 2023  
Noile-Immune Biotech, Inc.  
<https://www.noile-immune.com>

### **Announcement on the Termination of License Agreement for NIB102 and NIB103**

Noile-Immune Biotech, Inc. (hereinafter referred to as “Noile-Immune”) hereby announces that Noile-Immune received the following notification today regarding the license agreements with Takeda):

- Takeda has decided to terminate the license agreement for NIB102 (TAK102) and NIB103 (TAK103), thereby returning the rights for the development and commercialization of NIB102 and NIB103 to Noile-Immune.
- The reason for the termination of the license agreement for NIB102 and NIB103 is due to a strategic shift in Takeda’s development portfolio towards allogeneic cell therapies, and is not related to any concerns about the safety or efficacy of NIB102 and NIB103.

As a consequence of this termination, Noile-Immune will hold the rights of NIB102 and NIB103. Noile-Immune is going to discuss with Takeda regarding the transition of ongoing trials, transfer of the obtained data, handling of intellectual property rights, and settlement of termination fee paid by Takeda, so as to explore future options. It should be noted that the termination fee may vary depending on the details of the development costs incurred by Takeda to date and may not be applicable.

Additionally, Takeda holds 8,119,800 shares (representing 18.76%) of Noile-Immune, with the lock-up period for these shares extending until December 24, 2023. There are no specific agreements in place regarding Takeda’s continuous holding of these shares.

We do not anticipate any impact on the financial results of Noile-Immune for the fiscal year ending December 2023 due to this matter. However, should any matters arise that require disclosure, we will provide updates promptly.

Contact for inquiries or additional information  
2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan  
Noile-Immune Biotech, Inc.  
E-mail: [ir@noile-immune.com](mailto:ir@noile-immune.com)